SMC Evaluation Project Laura McIver, Dr Paul Catchpole,

Scottish Medicines Consortium

SMC Evaluation Project

Laura McIver, Dr Paul Catchpole,

On behalf of SMC Evaluation Management Group

ABPI Conference, 17th November 2006


Remit of Evaluation

• To assess the impact and effectiveness of SMC Advice in NHS Scotland

• To inform Scottish practice around managed introduction of new medicines

• To contribute to the wider understanding of organisations that assess new technologies


Project team:Bill Ramsay

Marion BennieCorri Black

Vicky CairnsSharon HemsSamuel Oduro

NHS/IndustryGroups/Networks

Management group

SMC reference group

SMC

Project Team Links


Industry and Organisations represented on the Reference Group

• Martin Coombes, AstraZeneca

• Andrew McGuigan, Janssen-Cilag

• Jim Swift, Takeda

• Patient and Public Representative

• Bipolar Fellowship Scotland

• HIV Scotland

• NHS ADTCs / Chief Executive / Director of Finance

• University Academics

• Scottish Executive Health Department


Programme Elements

SMC Evaluation Programme

Impact of SMC decisions on medicines utilisation across the health care

system.

Evaluation of SMC budget

forecasts with resource

usage within NHS Scotland

over time

Evaluation of SMC’s

engagement with key

stakeholders

Supporting linkage of

clinical information

and medicines utilisation data


Medicine Utilisation

Sample fromeach group selected. Reviewed and verified by

clinical networks and Reference Group

Classification of Medicines

Unique CancerAntimicrobials

Accepted Restricted

Not Recommended

Data (either per month or per quarter)

• volume/amount issued

• total cost/expenditure for the medicine

• no. of patients prescribed the medicine

Data Sources and CollectionPrimary care

- Information Services Division

Secondary Care- Pharmacy Systems and Clinicians

Pharmaceutical Industry


Data Sources and Collection

Analysis of data and draft report

Validation and Interpretationvia

Clinical Networks, ADTC Networks,Reference Group and Industry

Issue report

Medicine Utilisation


Classification of Data

Clinical Area

Recommendation type

Cancer Antimicrobials Unique / Innovative

Other Total

Accepted 10 4 1 53 68

Accepted for Restricted use

16 12 6 48 82

Not recommended

10 5 1 41 57

Total 36 21 8 142 207


Not Recommended MedicinesNot Recommended Medicinesin Primary Carein Primary Care

£0

£5,000

£10,000

£15,000

£20,000

£25,000

£30,000

£35,000

£40,000

2002/0

3 Q

3

2002/0

3 Q

4

2003/0

4 Q

1

2003/0

4 Q

2

2003/0

4 Q

3

2003/0

4 Q

4

2004/0

5 Q

1

2004/0

5 Q

2

2004/0

5 Q

3

2004/0

5 Q

4

2005/0

6 Q

1

2005/0

6 Q

2

2005/0

6 Q

3

2005/0

6 Q

4

Financial Year Quarter

Gro

ss I

ng

red

ien

t C

ost

Note: GIC obtained from Prescribing Information System for Scotland (PRISMS)Note: GIC obtained from Prescribing Information System for Scotland (PRISMS)

Not Recommended by SMC Restricted approvalby NICE


Outputs

• Scottish patients access to individual medicines reviewed by SMC

• Qualitative and quantitative data

• Generic key findings / learnings

• Recommendation next steps and actions


SMC Evaluation Programme

Evaluation of SMC’s engagement

with key stakeholders.

Patient and Public Involvement Sub-Group (PAPIG)

Pharmaceutical Industry

NHS

Scottish Centre for SocialResearch

ADTC role and processes reviewed

Key themes identified

Opportunity exists to share experience and identify examples of good practice


Engagement with Industry

• Industry can provide the project with important additional medicines uptake datasets:

• Secondary care

• Primary care

• To support both primary analysis (mainly secondary care) and to cross validate and supplement existing NHS datasets

• Evidence collection template (quantitative and qualitative data) presently being finalised for issue to companies


Summary

• Work programme progressing well and to plan

• Challenges around data collection which can partially be addressed by engagement of industry

• Validation and interpretation needs to be robust

• Contextual qualitative evidence also required to support the quantitative information gathered

• ABPI and industry support crucial to the project

SMC Evaluation Project Laura McIver, Dr Paul Catchpole,

Documents

Transcript of SMC Evaluation Project Laura McIver, Dr Paul Catchpole,